Kevin Mooney, chairman of the drafting committee for the Unified Patent Court (UPC)’s rules of procedure, explained the current state of play to the CIPA Life Sciences conference.
The EPO boards of appeal are unlikely to be able to reduce the case backlog anytime soon, but attorneys should be wary of possible changes in board practice, former board head Alec Clelland told the CIPA Life Sciences conference.
Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.
The FTC has issued final changes to the premerger notification rules that require pharmaceutical companies to report certain proposed patent right acquisitions to the commission and US Department of Justice for antitrust review.
The US District Court for the Northern District of California has dismissed biosimilar maker Sandoz’s motion for declaratory judgment that its etanercept product does not infringe biopharmaceutical company Amgen’s arthritis drug Enbrel.
UK-based drugmaker Shire plc announced on November 11 that it had acquired rare disease biopharmaceutical company ViroPharma in an agreement worth approximately $4.2 billion.
On November 5, the US Supreme Court heard oral arguments in the Medtronic Inc v Boston Scientific Corporation case to determine whether the patent holder or licensee bears the burden of proof in matters where declaratory judgment of non-infringement has been sought.
A federal court has upheld a ruling that biotech company Illumina should pay rival Syntrix $115 million and an 8 percent running royalty rate for patent infringement.
US pharmaceutical company Forest Laboratories and drug company Actavis have settled a legal dispute over a patent protecting blood pressure drug Bystoli (nebivolol).
The UK Patents Court has referred four questions to the CJEU seeking clarification on how the SPC Regulation should be interpreted in relation to drug products made of a combination of active ingredients.